ABBV - Needham says Abbvie's Botox sales results good news for Evolus Revance
2023-10-27 15:22:19 ET
More on AbbVie, Evolus, etc.
- AbbVie Inc. (ABBV) Q3 2023 Earnings Call Transcript
- AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans
- AbbVie: The Humira Loss May Be Fully Priced In After All
- AbbVie stock dips despite guidance boost (update)
- AbbVie Non-GAAP EPS of $2.95 beats by $0.08, revenue of $13.93B beats by $220M
For further details see:
Needham says Abbvie's Botox sales results good news for Evolus, Revance